What Happened? A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.5%, S&P 500 +1 ...

Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results tomorrow after the bell. Here’s what investors should know. 10x Genomics beat analysts’ revenue expectations by 3. ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results , with sales up 9.8% year on year to $154.9 million. On the other hand, next quarter’s revenue guidance of $140 million was ...

Genomics (TXG) closed the last trading session at $8.86, gaining 7.1% over the past four weeks, but there could be plenty of ...

10x Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Wall Street expects a year-over-year increase in earnings on lower revenues when 10x Genomics (TXG) reports results for the quarter ended March 2025. While this widely-known consensus outlook is ...

PLEASANTON, Calif., May 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has reached a settlement agreement with ...

10x Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results topping the market’s revenue expectations , with sales up 9.8% year on year to $154.9 million. On the other hand, next ...